Signal Genetics to release MyPRS Plus
According to the company, MyPRS Plus helps gain further insights of individual’s genetic characteristics and also determines the molecular sub-group to which each patient belongs. The relapse and
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.